Recruiting

MR Imaging

Sponsor:

Massachusetts General Hospital

Code:

NCT03032809

Conditions

CNS Vasculitis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Vessel Wall MR imaging

Study Details

Brief summary:

The aims of this study are to optimize MR imaging and MR angiography sequences and image reconstruction for 3T magnetic resonance imaging system scanners, which are already used in the clinical environment on patients with or with suspected intracranial vasculopathies. Improvements in these areas will have positive implications for medical diagnosis and treatment.

Conditions

CNS Vasculitis

Study ID

NCT03032809

Start date

Sep, 2018

Status verified date

Sep, 2018

Completion date

Jul, 2019

Anticipated

Primary completion date

Jul, 2019

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • adult (older than 18 years)

Exclusion Criteria:

  • electrical implants such as cardiac pacemakers or perfusion pumps
  • ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants
  • ferromagnetic objects such as jewelry or metal clips in clothing
  • pregnant subjects
  • pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions
  • any greater than normal potential for cardiac arrest

Study Design

Enrollment

50 participants

Anticipated

Interventions and Outcome Measures

Arms

Intracranial vasculopathy

Patients diagnosed intracranial vasculopathy will be imaged further by high resolution vessel wall MR imaging on a 3Tesla MR scanner.

Interventions

Vessel Wall MR imaging

Magnetic resonance images of the intracranial arteries will be acquired using the 3 Tesla MR scanners. Intracranial vessels will be imaged by high resolution vessel wall MR imaging to characterize vessel wall enhancement characteristics and wall thickness.

Primary outcome measure

  • Degree of intracranial artery vessel wall enhancement [ Time Frame: During acute phase of symptoms (approximately 0-14 days from onset of symptoms) ]

Central Contacts and Locations

Central contacts

Javier Romero, MD

6178402392jmromero@mgh.harvard.edu

Emmanuel Obusez, MD

6177268320EOBUSEZ@mgh.harvard.edu

Locations

Massachusetts General Hospital

Recruiting

Boston, Massachusetts, United States, 02114

Contacts

Emmanuel Obusez, M.D

617-726-8320EOBUSEZ@mgh.harvard.edu

More Information

Sponsor

Massachusetts General Hospital

Last update posted

Sep 17, 2018

Last verified

Sep, 2018

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Massachusetts General Hospital on 2018-09-17.